ApprovedFDA approval

Onswik (insulin efsitora alfa-gobe)

Eli Lilly (LLY)

Marketer take

Lilly's once-weekly basal insulin arrives six months after Novo Nordisk's Awiqli, setting up a direct weekly-insulin positioning fight in endocrinology and primary care where formulary placement decides early share.

Sponsor company
Eli Lilly (LLY)
Indication
To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
Therapeutic area
Diabetes, Metabolic
Event
FDA approval
Date
Sep 23, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move